WEBINAR Advancing CRISPR safety: An end-to-end genotoxicity assessment framework for rapid development of CRISPR-based therapies

As CRISPR-based therapies advance rapidly, ensuring off-target safety is critical, especially when timelines are short and clinical stakes are high.

This webinar introduces a comprehensive, scalable framework for off-target risk assessment that integrates orthogonal nomination strategies, including cell‑based (UNCOVERseq), in vitro (CHANGE-seq and ONE-seq), and in silico approaches. Designed to support rapid decision-making, this framework also helps researchers and developers prioritize and confirm off-target sites using targeted deep sequencing with our rhAmpSeq™ CRISPR Analysis System.

Link: Integrated DNA Technologies, Inc.